␤-Estradiol 17-(␤-D-glucuronide) (E 2 17G) is a well known cholestatic agent and substrate of multidrug resistance-associated protein 2 (Mrp2), whereas ␤-estradiol 3-(␤-D-glucuronide) (E 2 3G) is a noncholestatic regioisomer of E 2 17G with unknown transport properties. The purpose of this study was to compare and contrast the Mrp2-mediated transport of E 2 17G and E 2 3G. The full coding region of rat Mrp2 was cloned into the baculovirus genome, the recombinant baculovirus used to infect Sf9 cells, and ATP-dependent transport During pregnancy, mean plasma levels of free and conjugated estrogens increase dramatically with gestational age (Levitz and Young, 1977) . Additionally, 3-hydroxy glucuronidation of the steroid A ring appears to produce a unique terminal product in estriol metabolism, in contrast to the intermediary metabolism of other estriol conjugates (Levitz et al., 1984) . We have postulated that increased levels of cholestatic estrogen glucuronides, such as ␤-estradiol 17-(␤-D-glucuronide) (E 2 17G) and estriol 16␣-(␤-D-glucuronide) (E 3 16G), in pregnancy contribute to the decrease in bile secretory function observed in normal pregnancy. E 2 17G is a prototype cholestatic estrogen D-ring glucuronide in the rat model, whereas ␤-estradiol 3-(␤-D-glucuronide) (E 2 3G) is a choleretic A-ring glucuronide (Meyers et al., 1981) . The mechanistic basis for their differential effects on bile flow is unknown, but likely involves direct interactions with hepatic canalicular transporters. E 2 17G is a well established Mrp2 probe substrate (Gerk and Vore, 2002) , but it has not been determined whether E 2 3G is an Mrp2 substrate. E 2 3G inhibits 2,4-dinitrophenolglutathione transport in rat canalicular membrane vesicles , and its biliary excretion in Mrp2-deficient Eisai hyperbilirubinemic rats is diminished (Takikawa et al., 1996) , suggesting that E 2 3G is an Mrp2 substrate.
During pregnancy, mean plasma levels of free and conjugated estrogens increase dramatically with gestational age (Levitz and Young, 1977) . Additionally, 3-hydroxy glucuronidation of the steroid A ring appears to produce a unique terminal product in estriol metabolism, in contrast to the intermediary metabolism of other estriol conjugates (Levitz et al., 1984) . We have postulated that increased levels of cholestatic estrogen glucuronides, such as ␤-estradiol 17-(␤-D-glucuronide) (E 2 17G) and estriol 16␣-(␤-D-glucuronide) (E 3 16G), in pregnancy contribute to the decrease in bile secretory function observed in normal pregnancy. E 2 17G is a prototype cholestatic estrogen D-ring glucuronide in the rat model, whereas ␤-estradiol 3-(␤-D-glucuronide) (E 2 3G) is a choleretic A-ring glucuronide (Meyers et al., 1981) . The mechanistic basis for their differential effects on bile flow is unknown, but likely involves direct interactions with hepatic canalicular transporters. E 2 17G is a well established Mrp2 probe substrate (Gerk and Vore, 2002) , but it has not been determined whether E 2 3G is an Mrp2 substrate. E 2 3G inhibits 2,4-dinitrophenolglutathione transport in rat canalicular membrane vesicles , and its biliary excretion in Mrp2-deficient Eisai hyperbilirubinemic rats is diminished (Takikawa et al., 1996) , suggesting that E 2 3G is an Mrp2 substrate.
Mrp2-mediated transport of E 2 17G is required for its cholestatic activity, although the mechanism is not clear. E 2 17G does not induce cholestasis in TR Ϫ rats deficient in Mrp2, even though very high concentrations of E 2 17G were used, sufficient to achieve equal biliary concentrations of E 2 17G in wild-type Wistar and TR Ϫ rats (Huang et al., 2000) . These data imply that the interaction between Mrp2 and E 2 17G is essential for cholestasis. We therefore questioned whether the inability of E 2 3G to induce cholestasis is because it is not an Mrp2 substrate, or because its interaction with Mrp2 differs significantly from the interaction between Mrp2 and E 2 17G. E 2 17G is transported by several ATP-binding cassette (ABC) transporters, including MDR1 (Huang et al., 1998) , MRP1 (Keppler et al., 1997) , MRP2 (Keppler et al., 1997) , MRP3 (Hirohashi et al., 1999) , MRP4 (Zelcer et al., 2003b) , MRP7 (Chen et al., 2003) , and ABCG2 (breast cancer resistance protein; or mitoxantrone resistance transporter) (Suzuki et al., 2003) , but not MRP6 (Belinsky et al., 2002) . Additionally, E 2 17G is transported by the rat organic anion-transporting polypeptides 1 to 4 (Hagenbuch and Meier, 2003) . By contrast, little is known of the transport mechanisms for E 2 3G. E 2 3G is a poor inhibitor of MRP1-mediated transport of leukotriene C 4 and E 2 17G (Loe et al., 1996) , and is a low-affinity inhibitor of both MRP4 and MRP7, with IC 50 values near 100 M (Chen et al., 2003; Zelcer et al., 2003b ). E 2 3G (100 M) did not inhibit MDR1-mediated transport of E 2 17G, suggesting that E 2 3G is not an MDR1 substrate (Huang et al., 1998) . E 2 3G may be a substrate for rat organic anion-transporting polypeptide 1, since it inhibits E 2 17G transport with a K i of 9.7 Ϯ 0.7 M (Kanai et al., 1996) . Its substrate specificity for other transporters is unknown.
The purpose of this investigation was 1) to determine whether Mrp2 transports E 2 3G, 2) to determine whether rat Mrp2-mediated E 2 3G transport differs mechanistically from that of E 2 17G, and 3) to obtain estimates of the kinetic parameters describing these interactions. The present research indicates that E 2 3G, like E 2 17G, is a high-affinity Mrp2 transport substrate. However, unlike E 2 3G, E 2 17G transport exhibits marked positive cooperativity, indicating that E 2 17G, but not E 2 3G, activates an allosteric site in Mrp2.
Materials and Methods
3 H-E 2 17G (40 -45 Ci/mmol) and 3 H-E 2 3G (53-57 Ci/mmol) were obtained from PerkinElmer Life and Analytical Sciences (Boston, MA). Unlabeled estrogen conjugates (Fig. 1A ) and all other reagents were obtained from Sigma-Aldrich (St. Louis, MO).
The rat MRP2 plasmid was obtained from Dr. Peter Meier, and the full coding region was inserted into the pFastBac1 vector (Invitrogen, Carlsbad, CA) with a nine-amino acid carboxy-terminal hemagglutinin tag and recombined in DH10Bac Escherichia coli cells (Invitrogen) containing the baculovirus genome. A comparable carboxy-terminal 6ϫ-histidine tag does not inhibit Mrp2 function (Hagmann et al., 2002) . As a background control, the empty vector was also recombined as above, but without an insert. The recombinant bacmids were amplified, sequenced (Elim Biopharmaceuticals, Hayward, CA) to confirm the presence (or absence) of Mrp2, and transfected using CellFectin (Invitrogen) into Sf9 insect cells. The supernatant containing the recombinant baculovirus was harvested, amplified, and titered by a viral plaque assay. Sf9 cells (5 ϫ 10 8 cells) in suspension culture were infected (multiplicity of infection ϭ 3), and 64 to 68 h later, cell membranes for transport experiments were harvested by layering on 38% sucrose and collecting the layer at the buffer-sucrose interface (Ito et al., 2001c) . Membranes were vesiculated, snap frozen in liquid nitrogen, stored at Ϫ80°C, and designated as either Mrp2-or empty virus (EV)-infected cell membranes. Protein concentrations were determined by a modification of the method described using bovine serum albumin as a standard (Lowry et al., 1951) .
Expression of rat Mrp2 was determined by Western blotting using 0.5 g of sucrose-fractionated membrane protein. Proteins were denatured in the presence of sodium lauryl sulfate at 37°C for 30 min before loading onto an 8% Tris/glycine polyacrylamide Novex precast gel (Invitrogen), separated by standard electrophoresis, and transferred onto Polynitran nitrocellulose membranes (Schleicher & Schuell, Keene, NH). Membranes were blocked using 5% nonfat milk at room temperature for 1 h, and binding of primary antibody [mouse anti-human MRP2 (M 2 III-6); Alexis Biochemicals, San Diego, CA) and secondary antibody (sheep anti-mouse, horseradish peroxidase-conjugated; Amersham Biosciences Inc., Piscataway, NJ) was performed in 5% nonfat milk at room temperature for 1 h. Chemiluminescence detection was done using ECL-Plus (Amersham Biosciences Inc.) and exposure to Biomax MR film (Kodak, Rochester, NY) .
Transport experiments were performed in a Tris-sucrose buffer (Ito et al., 2001c) , containing 5 mM ATP or AMP, 10 mM MgCl 2 , 10 mM phosphocreatine, 100 g/ml creatine phosphokinase, and unlabeled estrogen conjugates in either dimethyl sulfoxide (0.5%) or 10:4:1 Tris-sucrose buffer/propylene glycol/ethanol (2%) as vehicles. Preliminary studies showed that the choice of vehicle had no effect on transport. ATP-dependent transport of 3 H-E 2 17G or 3 H-E 2 3G into membrane vesicles (10 g/20 l) was measured in incubations at 37°C for 2 to 5 min, transport was stopped with 3.5 ml of ice-cold stop buffer (Ito et al., 2001c) , and the mixture was quickly filtered onto Durapore 0.4-m filters (Millipore Corporation, Bedford, MA). The filters were selected due to their minimal binding of E 2 17G at low (90 nM) or high (100 M) concentrations. The tubes and filters were rinsed as described (Boyer and Meier, 1990) .
3 H collected on the filters was detected by liquid scintillation counting using scintillation counting cocktail (Bio-Safe II; Research Products International Corp., Mt. Prospect, IL).
Transport corrected for that in the presence of AMP was termed ATPdependent transport, whereas that corrected for background (EV) transport was termed Mrp2-mediated transport. Nonlinear regression was performed on saturation data by fitting the data to the Hill equation and weighting as indicated in figure legends. Other curves were unweighted for linear or nonlinear regression using Prism version 4 computer software (GraphPad Software Inc., San Diego, CA) for fitting as indicated in figure legends. Remaining data were analyzed by one-way analysis of variance (␣ ϭ 0.05) followed by Dunnett's multiple comparison test (Prism).
Results
The expected underglycosylated rat Mrp2 protein (Ͻ190 kDa) was detected in Mrp2-expressing Sf9 cell membrane vesicles by means of Western analysis (Fig. 1B) . Mrp2 was undetectable in the EV membrane vesicles.
The basic transport characteristics for E 2 3G and E 2 17G are shown in Fig. 2 . To ensure that transport properties and kinetic values were attributable to Mrp2, transport studies were carried out in sucrosefractionated Sf9 plasma membranes, and transport in Mrp2-expressing membranes was corrected for that in membranes from cells transfected with the EV. Transport of both compounds was linear to at least Filled or empty symbols represent data obtained from Mrp2-expressing or EV vesicles, respectively. A and B, E 2 3G (30 nM) and E 2 17G (77 nM) transport as a function of time. C and D, effect of sucrose (osmolarity) on E 2 3G (30 nM) and E 2 17G (77 nM) transport. Squares or circles represent data obtained in the presence of ATP or AMP, respectively. E, saturation of E 2 3G transport. Nonlinear regression was performed fitting the data from two independent experiments (triplicate determinations) to the Hill equation, with a weighting factor of 1/y5 min and was much greater in membrane vesicles expressing Mrp2 versus EV (Fig. 2, A and B) . Similarly, transport of both compounds occurred into an osmotically sensitive space with a y-intercept close to zero, indicating that observed activity was mainly transport and binding was minimal (Fig. 2, C and D) . Additionally, transport of both compounds was linear with respect to protein (data not shown). Mrp2-mediated ATP-dependent transport of E 2 3G (Fig. 2E ) was fit to a single apparent saturable transport site with S 50 ϭ 55.7 (95% CI 44.2-70.1) M and V max ϭ 326 (95% CI 286 -366) pmol ⅐ mg Ϫ1 ⅐ min Ϫ1 , and a Hill coefficient of 0.88 (95% CI 0.85-0.91). Figure 2F shows the combined results of three independent saturation experiments with E 2 17G. Fitting the data to simple linear (nonsaturable), one-site and two-site Michaelis-Menten equations and the Hill equations yielded the lowest Akaike information criteria (Prism 4.0) for the fit to the Hill equation, indicating that the fit to the Hill equation was best supported by the data. Due to the limited solubility of E 2 17G, we were unable to fully saturate the transport to obtain unique estimates for V max and K m ; however, for Mrp2-mediated transport, the data were best fit to an unweighted Hill equation with a Hill slope of 1.5 Ϯ 0.2. These data suggest positive cooperativity for E 2 17G transport. Notably, E 2 17G association with either Mrp2 or EV membrane vesicles in the absence of ATP was not influenced by E 2 17G concentration (0.02-160 M) or by any other agent used here. Also, ATPdependent transport of E 2 3G and E 2 17G in EV membranes followed simple Michaelis-Menten kinetics (Hill slope ϭ 1), with K m values of 221 (95% CI 100 -490) M and 56.2 (95% CI 33.2-79.3) M, and V max values of 132 (95% CI 40 -225) and 135 (95% CI 104 -166) pmol ⅐ mg Ϫ1 ⅐ min Ϫ1 , respectively. Finally, E 2 3G was more soluble than E 2 17G under identical experimental conditions, avoiding solubility problems that occur at high E 2 17G concentrations.
To better understand the structure-activity relationships among relevant estrogen glucuronides (Fig. 1A) and Mrp2, we compared E 2 17G and E 2 3G transport, and the effects of E 3 16G, a weak cholestatic glucuronide (Meyers et al., 1981) and ␤-estradiol 3-sulfate 17-(␤-D-glucuronide) (E 2 3SO 4 17G), a naturally occurring choleretic biliary estradiol metabolite (Meyers et al., 1980; Takikawa et al., 1996) , on their transport. The results for E 2 17G transport are shown in Fig. 3 . Again, unique fits were not obtained for the E 2 17G saturation data due to its limited solubility (Fig. 2F ), but the data were best fit to the Hill equation with a Hill coefficient of 1.5. E 2 3G (15 M, Fig. 3A) shifted the entire E 2 17G transport versus concentration curve (Hill coefficient fixed at 1.5) to the right, consistent with competitive inhibition for transport. E 2 3G (IC 50 ϭ 14.2 M, 95% CI 7.8 -25.7 M, Fig. 3B ) was a complete and high-affinity inhibitor of E 2 17G transport. Additionally, E 2 3SO 4 17G (5-50 M) potently and completely (50 M) inhibited transport of E 2 17G (Fig. 3C) . Association or diffusion of E 2 17G into either Mrp2 or EV membranes in the absence of ATP did not change with the concentrations tested. Concentrations of 3 H-E 2 17G above 250 M increased the radioactivity collected on the filters in the absence of ATP, suggesting precipitation from solution. Furthermore, both MDR1-mediated E 2 17G transport in Sf9 membranes (Huang et al., 1998 ) and E 2 17G transport by EV membranes in the present studies adhered to Michaelis-Menten kinetics. The data are therefore not consistent with nonspecific effects of E 2 17G on the cell membrane.
Similar studies on E 2 3G transport are shown in Fig. 4 . E 2 17G only partially inhibited (53%) E 2 3G transport with an IC 50 ϭ 33.4 M (95% CI 26.4 -45.2 M; Fig. 4A ). In contrast, E 3 16G was a complete and high-affinity inhibitor of E 2 3G transport (IC 50 ϭ 2.23 M, 95% CI 2.07-2.40 M; Fig. 4B ). Competitive inhibition studies were performed with E 2 17G (5-125 M) and E 2 3SO 4 17G (5 M) (Fig. 4,  C and D) , and the nonlinear regression fit to the Hill equation (Table  1) . Neither E 2 17G nor E 2 3SO 4 17G had a significant effect on the V max for E 2 3G transport; as a result, V max was shared for all the data sets. However, both E 2 17G and E 2 3SO 4 17G significantly increased the apparent S 50 for E 2 3G transport, indicative of competitive inhibition at the transport site. E 2 3SO 4 17G and the highest E 2 17G concentration also slightly increased the Hill coefficients closer to unity.
Discussion
The purpose of the present studies was to determine whether E 2 3G is a substrate of Mrp2, to determine whether the noncholestatic E 2 3G and the cholestatic E 2 17G exhibited similar Mrp2-mediated transport properties, and to obtain estimates of the kinetic parameters for their transport. The present data clearly demonstrate that E 2 3G is an excellent substrate for Mrp2, having an S 50 of 55.7 M and a V max of 326 pmol/mg/min. Thus, although several permissive multidrug resistance transporters such as P-glycoprotein and the MRPs transport E 2 17G, E 2 3G is most likely not a substrate for MDR1 and MRP1 (Loe et al., 1996; Huang et al., 1998) , as mentioned previously. This suggests a potentially important difference in the substrate specificities of MRP1 and Mrp2/MRP2. Thus, if E 2 3G is transported by Mrp2 but not other MRPs or MDR1, E 2 3G would be a more selective probe than E 2 17G for MRP2-mediated transport. The higher water solubility of E 2 3G also increases its experimental utility. The data also establish Mrp2 as a hepatic efflux mechanism for E 2 3G, and are consistent with data demonstrating the choleretic activity of E 2 3G (Meyers et al., 1980) and its biliary excretion in normal rats (Takikawa et al., 1996) . Although E 2 3G is not overtly toxic, its biliary excretion is important due to the complex pattern of interconversion among the estrogen metabolites (Levitz and Young, 1977; Levitz et al., 1984) . During the preparation of this article, ethinyl-estradiol-3-glucuronide, a structural analog of E 2 3G, was also shown to be transported by human MRP2 but not MRP1 (Chu et al., 2004) , consistent with the present findings.
The present data also indicate that the interactions between E 2 3G and E 2 17G and Mrp2 are very distinct. The Hill coefficient for Mrp2-mediated E 2 3G transport was slightly, but significantly less than unity (0.88). Although the significance of this negative cooperativity is not known, it could contribute to the somewhat higher S 50 (56 M) obtained for E 2 3G transport versus its IC 50 to inhibit E 2 17G transport (14.2 M). In contrast, E 2 17G transport occurred with significant positive cooperativity (Hill coefficient of 1.5). Our preliminary data also indicate a Hill coefficient of 2 for human MRP2-mediated E 2 17G transport (Gerk et al., 2003) . Studies reporting K m values of 3 to 8 M for rat Mrp2 expressed in Sf9 cells (Ito et al., 2001b,c) or in HEK-293 cells (Cui et al., 1999) did not examine the range of E 2 17G concentrations used here. At higher concentrations, E 2 17G exhibited nonclassical transport kinetics, consistent with allosteric activation of its transport, as recently proposed for human MRP2 ( cells clearly possess endogenous transporter(s) for both E 2 17G and E 2 3G, with K m estimates of 56.2 and 221 M, respectively. It was necessary to correct for this endogenous transport activity, which became significant at high substrate concentrations, to obtain accurate estimates of the distinct kinetic parameters for Mrp2-mediated transport of E 2 17G and E 2 3G. Evidence for two sites for E 2 17G transport was also observed in the pattern of inhibition by other estrogen glucuronides. E 2 3G and E 2 3SO 4 17G completely and potently inhibited E 2 17G transport. Also, transport of E 2 3G was potently inhibited by E 3 16G (IC 50 2.23 M) and competitively inhibited by E 2 3SO 4 17G. Conversely, however, E 2 17G did not completely inhibit E 2 3G transport within the limits of E 2 17G solubility. The data are consistent with a model in which E 2 3G and E 2 17G compete for binding to the Mrp2 transport site, as evidenced by the increased S 50 for E 2 3G transport ( Fig. 4C; Table 1 ) and the rightward shift of E 2 17G transport in the presence of E 2 3G (Fig.  3A) . E 2 3G transport clearly does not demonstrate positive cooperativity, and therefore, E 2 3G does not activate the allosteric site. The slight negative cooperativity of E 2 3G transport (Hill coefficient 0.88) may reflect antagonism rather than activation of the allosteric site. The data in Fig. 4 , A and C, support a model with an allosteric site having low affinity for E 2 17G (K m Ͼ100 M). Accordingly, low concentrations of unlabeled E 2 17G competitively inhibit the transport of low concentrations of 3 H-E 2 3G or 3 H-E 2 17G, but as E 2 17G concentrations increase, activation at the allosteric site would occur concurrently with competition for the transport site. Such a model with concurrent activation and competition explains the positively cooperative transport of E 2 17G and the inability of E 2 17G to completely inhibit E 2 3G transport, as well as the lack of further increase in S 50 for E 2 3G transport with increasing E 2 17G concentrations ( Table 1 ). The ability of E 3 16G and E 2 3SO 4 17G to completely and potently inhibit transport also provides information on the nature of the transport site versus the allosteric site. The fact that E 2 3SO 4 17G inhibits completely indicates that sulfation of the A-ring of E 2 17G abolished its ability to activate the allosteric site and implies that a phenolic A-ring is important for binding to this site. However, E 3 16G, which like E 2 17G is a glucuronide conjugate of the steroid D-ring with a phenolic A-ring, was also a potent and complete competitive inhibitor of E 2 3G transport (IC 50 2.2 M); these data are also consistent with E 3 16G having negligible activity at the allosteric site. These latter data indicate that the phenolic A-ring on a steroid glucuronide alone is not sufficient to activate the allosteric site; the greater hydrophilicity of E 3 16G and/or the different stereochemistry of the glucuronic acid at the 16␣-OH of estriol versus the 17␤-OH of estradiol are also likely critical factors that decrease activation of the allosteric site. Finally, these data indicate that the transport site is much more permissive than is the allosteric activation site.
The presence of more than one binding site on Mrp2 is consistent with findings with other ABC transporters that mediate efflux of xenobiotics and their conjugates. P-Glycoprotein has three proposed binding sites, including two transport sites and an allosteric site (Shapiro et al., 1999) . The existence of this MDR1 allosteric site was recently confirmed (Maki et al., 2003) , demonstrating that this allosteric site influences substrate translocation and its subsequent dissociation from MDR1. Separate binding sites for E 2 17G and sulfinpyrazone have been postulated for human MRP2, based on substitutions at W1254 (Ito et al., 2001a) . The W1254F MRP2 mutant retained E 2 17G transport, but not leukotriene C 4 or methotrexate transport. These authors concluded that each MRP2 substrate interacts with a unique, but overlapping set of contacts in a multipartite substrate-binding pocket. Also, Evers et al. (2000) postulated two MRP2 transport sites with positive cooperativity to explain the ability of sulfinpyrazone and indomethacin to stimulate glutathione transport. Whether the allosteric site described in the present studies represents another drug transport site or a third allosteric site is not clear. To date, E 2 17G appears to be the only Mrp2 substrate that is able to activate its own transport.
The present data raise important questions regarding the physiological, pharmacological, and toxicological consequences of the ability of E 2 17G to allosterically activate Mrp2 transport activity. The data suggest that binding of high, cholestatic concentrations of E 2 17G to Mrp2 could lead to a marked stimulation of its transport into the canaliculus. Administration of E 2 17G leads to endocytic retrieval of Mrp2 and Bsep from the canalicular membrane, thus decreasing their ability to transport osmotically active solutes into bile and decreasing bile flow (Mottino et al., 2002; Crocenzi et al., 2003) . A key question is whether E 2 17G-induced activation of Mrp2 is causally related to E 2 17G-induced internalization of Mrp2 and Bsep and cholestasis. Cell shrinkage has been shown to cause internalization of transporters and cholestasis (Haussinger et al., 2000) , but at present, there is no evidence for a mechanistic link between Mrp2 activation and decreased cell volume sufficient to trigger such internalization. In the presence of Mrp2, E 2 17G enhances activation of chloride channels and, in cells swollen with hypotonic media, causes cell shrinkage (Li and Weinman, 2002) . Further studies are needed to determine whether E 2 17G-induced activation of Mrp2 sufficient to cause Mrp2 and Bsep retrieval is preceded by shrinkage of hepatocytes.
The ability of estrogen glucuronides to serve as Mrp2 substrates and competitively inhibit Mrp2 transport may contribute to the decreased bile secretory function observed in normal pregnancy, and to intrahepatic cholestasis of pregnancy observed in some women. Although E 3 16G has a lower cholestatic potency (29%) compared with E 2 17G in animal models (Meyers et al., 1980) , the concentrations of E 3 16G (ϳ100 nM) in human plasma at term of uncomplicated pregnancy are much greater than those of E 2 17G (14 nM) (Levitz and Young, 1977; Numazawa et al., 1979) . The present data show that E 3 16G is a potent inhibitor of Mrp2, with an IC 50 value near 2 M. Increased concentrations of E 3 16G during normal pregnancy may reach levels in the hepatocyte sufficient to inhibit MRP2. Further- dmd.aspetjournals.org more, both E 2 17G and E 2 3G inhibit glutathione biliary excretion . In intrahepatic cholestasis of pregnancy, a vicious cycle may occur in which the accumulation of cholestatic estrogen glucuronides progressively inhibits MRP2 function by direct competitive inhibition as well as by triggering transporter retrieval, thus leading to further accumulation of cholestatic estrogen glucuronides and worsening of cholestasis.
In conclusion, these data provide direct evidence that E 2 3G, like E 2 17G, is transported by Mrp2, whereas E 2 3SO 4 17G and E 3 16G are potent inhibitors of Mrp2 transport, consistent with their also being Mrp2 substrates. The interactions between Mrp2 and E 2 17G are complex and require more than one distinct binding site. The data are consistent with a model in which E 2 17G interacts with a transport site and an allosteric site that increases its own transport. E 2 17G and E 2 3G compete for binding to the transport site, but E 2 3G does not activate the allosteric site. Mrp2 thus plays a major role in the biliary excretion of both cholestatic and noncholestatic estrogen glucuronides. Further studies are needed to identify the binding sites for E 2 17G on Mrp2 and to determine whether there is a link between the binding of E 2 17G to the allosteric site and its cholestatic activity.
